Abbott (ABT) Stock Analysis
NYQ · Healthcare · Medical Devices
$100.77
-0.53 (-0.52%)
ABT Interactive Price Chart & Trading Signals
ABT Stock Snapshot — Valuation, Risk & Technical Signals
ABT Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$174.36B
P/E Ratio
32.61
Forward P/E
16.61
PEG Ratio
1.86
P/B Ratio
3.41
EPS
$3.09
Dividend Yield
2.49%
52W Range
$81.97 – $135.45
Beta
0.59
Volume
1.0M
ROE
10.6%
Profit Margin
11.6%
Revenue Growth
13.0%
Gross Margin
56.8%
EV/EBITDA
17.38
Analyst Target
$120.26
The trailing price-to-earnings ratio stands at 32.6x. Forward P/E of 16.6x implies earnings expansion expected. Price-to-book is 3.41x. EV/EBITDA sits at 17.38x. Market capitalization is $174.36B. Revenue is growing at 13.0% on a trailing basis. Earnings are compressing at -47.5%. Profit margins are 11.6%. Return on equity is 10.6%. Beta of 0.59 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$103.00
Mean Target
$120.26
High Target
$135.00
Based on 25 analysts
About Abbott
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
ABT Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Abbott Laboratories (ABT) trades above our multi-model fair value estimate of $52.73 by approximately 47.7%. Trailing P/E: 32.6x. Profitability signals include profit margin of 11.6% and return on equity of 10.6%. Recent growth metrics show revenue growth of 13.0% and earnings growth of -47.5%. Risk profile: defensive beta of 0.59. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 32.6x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 13.0%
Revenue is outpacing the market.
Risk
Low
Beta 0.59
Movement is likely to track the broader market.
Valuation Snapshot
Abbott Laboratories (ABT) trades above our multi-model fair value estimate of $52.73 by approximately 47.7%. The trailing price-to-earnings ratio stands at 32.6x. Forward P/E of 16.6x suggests earnings compression ahead. Price-to-sales is 3.7x. Price-to-book is 3.4x. EV/EBITDA sits at 17.4x. Market capitalization is $174.36B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 13.0% on a trailing basis. Earnings are compressing at -47.5%. Profit margins are 11.6%. Return on equity is 10.6%. Return on assets is 5.3%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.59 indicates defensive profile. Net debt position is $27.12B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $120.26 implies 19.4% upside. Target range spans $103.00 to $135.00. 25 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
ABT Overvalued
Abbott Laboratories (ABT) trades above our multi-model fair value estimate of $52.73 by approximately 47.7%.
Frequently Asked Questions
ValuationIs ABT stock overvalued right now?
ValuationWhat is ABT fair value based on current fundamentals?
RiskHow risky is ABT compared with other stocks?
GrowthIs ABT still growing?
AnalystWhat do analysts think about ABT?
DividendDoes ABT pay a dividend?
CatalystWhat could change the investment case for ABT?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.